Please login to the form below

Not currently logged in
Email:
Password:

Takeda extends its operations

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland to cover the entire country.

The company now has sales and marketing divisions in eight European countries. In addition to Spain and Ireland, there are wholly-owned subsidiaries in France, UK, Italy, Germany, Austria and Switzerland.

Subsidiary, Takeda Farmacéutica España SA, will start promoting Blopress (candesartan cilexetil), an antihypertensive therapy known as Amias in the UK, and Actos (pioglitazone HCl) one of Takeda's two therapies for Type II diabetes.

In the Republic of Ireland, Takeda expanded promotional activities for Actos in January this year, having been active in a specific part of the country only.

Eric Brunn, CEO of Takeda Pharmaceutical Europe, Takeda's UK subsidiary said: "We are pleased with the expansion of geographical coverage in Spain, one of the most important markets in Europe, and also the nationwide coverage in the Republic of Ireland. We will actively introduce products from our portfolio into these two countries."

In 2004, Takeda received approval for Blopress to be used in the treatment of chronic heart failure (CHF). Candesartan is marketed worldwide as Blopress (or Amias) by Takeda and under the brand name of Atacand by AstraZeneca in more than 70 countries.

30th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics